SLC5A2 and type 2 diabetes mellitus: The Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation-3 (ROTATE-3) was an open-label, randomized, crossover trial that explored the albuminuria-lowering effects of the SGLT-2 inhibitor dapagliflozin (10 mg/day) and the steroidal MRA eplerenone (50 mg/day), administered either individually or in combination, in 48 CKD patients with or without T2D [45].